Dear Sir/Madame,
I am Visiongain
Who we are:
I am writing to you because you are a known professional/company in the industry who may have an interest in this report. For this reason I would like to bring to your attention a comprehensive report from Visiongain
Top-10 Biotech Companies - Market Outlook, 2008-2023
- Publication date: 04/12/2008
- Number of Pages: 157
Please read on to find further details of this report, if you have any enquiries or further questions please contact me.
You can find details of all our reports and upcoming conferences on our website:
http://www.visiongain.com/site.aspx?p=8
You will automatically receive a 10% discount on ALL reports and conferences by replying to this email. Details on How to Order can found at the end of this correspondence.
Report Pricing Options:
Single User GBP £1499
Departmental (Five Users) GBP £2999
Site GBP £4999
Global Site GBP £6999
Report Details
The biotechnology industry is a major growth area in the global healthcare market, one upon which many companies are placing their hopes. Due to developments in monoclonal antibodies, genomics and proteomics - amongst others - the biotechnology market has experienced great expansion since its emergence during the 1970's. The leading healthcare biotechnology company, Amgen, is now amongst the largest pharmaceutical companies in the world, with other healthcare biotech companies catching up. The global biotech drug market was worth over $75bn in 2007, with double-figure growth noticeably higher that that of the overall pharmaceutical market. Our new report - Top-10 Biotech Companies - Market Outlook, 2008-2023 - will help you to understand those developments and their significance. That report provides valuable commercial information on this exciting industry that no healthcare company should ignore.
Over the period 2008 to 2023, visiongain foresees the healthcare biotechnological market continuing its strong growth, with exciting new developments both technologically and commercially. Increased R&D efforts, shorter approval times and innovative new treatments are aiding market growth. However, the two major threats the healthcare biotechnology sector faces in the coming years are the increasing threat of biogenerics and the difficulty in acquiring capital. Strategic partnerships will continue to be important to biotechnological drug development. There remain significant unmet needs in this market, with great opportunities for companies that can develop safer and better-targeted treatments.
Top-10 Biotech Companies - Market Outlook, 2008-2023 examines the product portfolios of the leading companies critically, with in-depth analysis, especially market forecasting and qualitative analysis of market drivers and restraints. The result is a comprehensive market-based report with detailed analysis and informed opinion.
Why you should buy this report:
In particular, Top-10 Biotech Companies - Market Outlook, 2008-2023 concentrates on the following essential aspects of the healthcare biotech market:
• Achievements and aspirations of global healthcare biotechnology
• Detailed sales forecasts from 2008-2023 for the sector, leading biotech companies and their main products
• Issues affecting the sector
• Discussion of drivers and opportunities
• Discussion of restraints and threats
• Detailed analyses of the top-10 healthcare biotech companies from 2008 onwards
• Salient pipeline developments in biotechnology and their implications for the future.
In 2007, the global revenues generated by the top-10 biotech companies exceeded $45bn. Amgen, Genentech and UCB are good examples of leading companies that have experienced strong sales growth in recent years. Principal drugs developed and marketed by the leading companies include Aranesp, Mabthera and Keppra, each with blockbuster sales. Moreover, pipelines of the leading biotech companies remain strong.
The leading healthcare biotechnology companies will continue to make strong inroads into the overall global pharma industry and market in the years ahead, with rising stars competing too. Do you know how sales of leading biotech companies will develop over the coming years? Do you know the prospects for other biotech organisations? Visiongain concludes that there will be increasing reliance on biological drugs as time goes by, especially for recalcitrant diseases with significant unmet needs. The commercial and technological opportunities for greater personalisation of medicine through biotechnology are very exciting. Certainly, the commercial opportunities for dynamic healthcare biotech companies are significant. The development of more-personalised medicine promising greater efficacy and safety - particularly in cancer treatment - is a major commercial hope. By purchasing this report, you will be better prepared to appreciate those major developments in the global pharmaceutical market.
Table of Contents
1. Executive Summary
2. Introduction to Biotechnology
2.1 Background to Biotech Drugs
2.1.1 Commonly-Used Terminology
2.1.2 Summary of Recombinant DNA Technology
2.1.3 Classes of Biotech Drugs
2.2 Biotech Drugs are Gaining Increasing Importance
2.2.1 Biopharmaceuticals are Versatile Agents
3. The World Biotech Market Analysis & Forecast 2008 & 2023
3.1 World Biotech Market Expanding Rapidly
3.2 Biotech Market Revenues Grew Significantly in 2007
3.3 Biotech Market Revenues Forecast 2008-2023
3.4 The World Biotech Market is Dominated by North America
3.5 Big Pharma Generates Strong Biotech Drug Revenues in 2007
3.6 Amgen Records Largest Sales in the Global Biotech Industry in 2007
4. Market Drivers and Restraints in the Global Biotech Market
4.1 SWOT Analysis for the Biotech Market
4.2 The Principal Drivers in the Biotech Market
4.3 The Principal Restraints in the Biotech Market
4.4 The Benefits of Biotechnology-Based Products
4.5 Biotech Industry Market Capitalisation Gains Momentum
4.6 Landmark Biotech Financing in 2007
4.7 Healthcare Biotech Venture Capitalist Deals in 2007
4.8 Healthcare Biotech VC Fund Investments
4.9 Healthcare Biotech IPOs Funds in 2007
4.10 New Technology Platforms in Biotech R&D
4.10.1 The Application of Genomic Technology in R&D
4.10.2 Leading Genomics Companies Benefit Through Lucrative Deals with Biotech and Big Pharma
4.10.3 The Application of Proteomics in Drug Discovery Widens
4.11 Pharmacogenomics is Crucial to Biotech Revenue Prospects
4.11.1 Pharmacogenomics Holds Potential Benefits
4.11.2 Biomarkers Add to Biotech Technology
4.12 US-Style Advance Technology Platform (ATP)
4.13 Collaborative Deals That Foster Genomic Applications
4.14 Rapidly Expanding Biotech Market Has Marked Challenges Ahead
4.15 Increasing Use of Pharmacoeconomic Evaluations is Having an Impact on Revenues of Biotech Medicines
4.16 Biotech Companies Must Improve Safety Profile of Drugs
4.17 Lack of Adequate Reimbursement Will Impede Potential Growth of the Biotech Market
4.18 Potential Growth in Biogenerics (Biosimilars) Market Will Hamper Revenues of Branded Biotech Drugs
4.19 EU Leads the Way in Biogenerics Market
4.20 The US Awaits New Biogenerics Regulatory Framework
4.21 US Congressional Budget Office (CBO) Estimates Biogenerics Will Help Reduce Drug Bills in the Long-Term
4.22 Biogenerics Manufacturers Will Face Several Hurdles Despite Lucrative Prospects
4.23 European Drug Regulation Framework Promises Increasing Entry of Biogenerics
4.24 European Medicines Agency (EMEA) Amends its Biogeneric Regulation
4.25 The Future of Healthcare Biotech looks Promising
5. Top-10 Biotech Companies Forecast & Analyses 2008-2023
5.1 Top-10 Biotech Companies Revenue Trends Looking Forward
6. Amgen
6.1 Key Therapeutic Areas
6.1.1 Cancer
6.1.2 Inflammation
6.1.3 Neurology
6 1.4 Metabolic Disorders
6.1.5 Haematology
6.2 Amgen Key Financials
6.3 Amgen Revenue Forecast 2008-2023
6.4 Amgen's Leading Drugs
6.4.1 Amgen's Leading Drug Sales, 2007
6.5 Amgen's Geographical Sales
6.6 Amgen's Top-Three Drugs - Sales Forecasts 2008-2013
6.7 Amgen's Phase III Pipeline
7. Genentech
7.1 Key Therapeutic Areas
7.2 Genentech Key Financials
7.3 Genentech Revenue Forecast 2008-2023
7.4 Genentech's Leading Drugs
7.5 Genentech's Geographical Sales
7.6 Genentech's Top-Three Drugs - Sales Forecasts 2008-2013
7.7 Genentech's Phase III Pipeline
8. UCB
8.1 Key Therapeutic Areas
8.2 UCB Key Financials
8.3 UCB Revenue Forecast 2008-2023
8.4 UCB's Leading Drugs
8.4.1 UCB's Leading Drugs Sales, 2007
8.5 UCB's Geographical Sales
8.6 UCB's Top-Three Drugs - Sales Forecasts 2008-2013
8.7 UCB's Phase III Pipeline
9. Gilead Sciences
9.1 Key Therapeutic Areas
9.2 Gilead Sciences Key Financials
9.3 Gilead Sciences Revenue Forecast 2008-2023
9.4 Gilead Sciences' Leading Drugs
9.5 Gilead Sciences Geographic Sales
9.6 Gilead Sciences' Top-Three Drugs - Sales Forecasts 2008-2013
9.7 Gilead Sciences' Phase III Pipeline
10. Genzyme
10.1 Key Therapeutic Areas
10.2 Genzyme Key Financials
10.3 Genzyme Revenue Forecast 2008-2023
10.4 Genzyme's Leading Drugs
10.5 Genzyme's Geographical Sales
10.6 Genzyme's Top-Three Drugs - Total Sales Forecasts 2008-2013
10.7 Genzyme's Phase III Pipeline
11. Biogen Idec
11.1 Key Therapeutic Areas
11.2 Biogen Idec Key Financials
11.3 Biogen Idec Revenue Forecast 2008-2023
11.4 Biogen Idec's Leading Drugs
11.5 Biogen Idec's Geographical Sales
11.6 Biogen Idec's Top-Two Drugs - Sales Forecasts 2008-2013
11.7 Biogen Idec's Phase III Pipeline
12. CSL
12.1 Key Therapeutic Areas
12.2 CSL Key Financials
12.3 CSL Revenue Forecast 2008-2023
12.4 CSL's Leading Drugs
12.5 CSL's Geographical Sales
12.6 CSL's Top-Three Drugs - Sales Forecasts 2008-2013
12.7 CSL's Phase III Pipeline
13. Cephalon
13.1 Key Therapeutic Areas
13.2 Cephalon Key Financials
13.3 Cephalon's Revenue Forecast 2008-2023
13.4 Cephalon's Leading Drugs
13.5 Cephalon's Geographical Sales
13.6 Cephalon's Top -Three Drugs - Sales Forecasts 2008-2013
13.7 Cephalon's Phase III Pipeline
14. Celgene
14.1 Key Therapeutic Areas
14.2 Celgene Key Financials
14.3 Celgene Revenue Forecast 2008-2023
14.4 Celgene's Leading Drugs
14.5 Celgene's Geographical Sales
14.6 Celgene's Top-Three Drugs - Sales Forecasts 2008-2013
14.7 Celgene's Phase III Pipeline
15. Actelion
15.1 Key Therapeutic Areas
15.2 Actelion Key Financials
15.3 Actelion Revenue Forecast 2008-2023
15.4 Actelion's Leading Drugs
15.5 Actelion's Geographical Sales
15.6 Actelion's Top-Three Drugs - Sales Forecasts 2008-2013
15.7 Actelion's Phase III Pipeline
16. Conclusions
16.1 Biopharmaceutical Treatment Options Expand Significantly over Past Two Decades
16.2 Biotech Industry Market Capitalisation Increases
16.3 Biotech Market Generated Significant Revenues in 2007
16.4 Overall Global Biotech Sales Prospects During the Forecast Period
16.5 Prospects for the Top-10 Biotech Companies
16.6 Big Pharma's Presence in the Biotech Arena
16.7 Potential Growth in the Biogenerics Market
16.8 The US Awaits Consolidation of Biogenerics Regulatory Framework
16.9 Prospects for the Healthcare Biotech Market Leaders
List of Tables
Table 3.1 Global Biotech Market Revenues ($m) Forecast 2008-2023
Table 3.2 Global Market Share (%) and Revenue ($m) by Country/Region, 2007
Table 3.3 Big Pharma's Biotech Revenue ($m), 2007
Table 3.4 Top-10 Biotech Companies ($m), 2007
Table 4.1 Biotech Market SWOT Analysis
Table 4.2 Biotech Market Capitalisation ($bn) over 10-Year Period, 1997-2007
Table 4.3 Patent Expiration of Leading Biotech Drugs
Table 5.1 Top-10 Biotech Companies Revenues ($m) Forecast, 2008-2023
Table 6.1 Amgen Revenues and Net Income ($m), 2003-2007
Table 6.2 Amgen: Total Corporate Revenues ($m), 2008-2023
Table 6.3 Amgen Leading Drug Sales ($m), 2007
Table 6.4 Amgen's Geographical Sales ($m), 2007
Table 6.5 Amgen's Top-Three Drugs - Sales ($m) Forecast, 2008-2013
Table 6.6 Amgen's Phase III Pipeline, 2008
Table 7.1 Genentech Revenues and Net Income ($m), 2003-2007
Table 7.2 Genentech: Total Corporate Revenues ($m), 2008-2023
Table 7.3 Genentech's Leading Drugs ($m), 2007
Table 7.4 Genentech's Geographical Sales ($m), 2007
Table 7.5 Genentech's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Table 7.6 Genentech's Phase III Pipeline, 2008
Table 8.1 UCB Revenues and Net Profit ($m), 2003-2007
Table 8.2 UCB: Total Corporate Revenues ($m), 2008-2023
Table 8.3 UCB's Leading Drugs ($m), 2007
Table 8.4 UCB's Geographical Sales ($m), 2007
Table 8.5 UCB's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Table 8.6 UCB's Phase III Pipeline, 2008
Table 9.1 Gilead Sciences Revenues ($m), 2003-2007
Table 9.2 Gilead Sciences: Total Corporate Revenues ($m), 2008-2023
Table 9.3 Gilead Sciences' Leading Drugs Sales ($m), 2006-2007
Table 9.4 Gilead Sciences' Geographical Sales ($m), 2007
Table 9.5 Gilead Sciences' Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Table 9.6 Gilead Sciences' Phase III Pipeline, 2008
Table 10.1Genzyme Revenues ($m), 2003-2007
Table 10.2 Genzyme: Total Corporate Revenues ($m), 2008-2023
Table 10.3 Genzyme's Leading Products ($m), 2006-2007
Table 10.4 Genzyme's Geographical Sales ($m), 2006
Table 10.5 Genzyme's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Table 10.6 Genzyme's Phase III Pipeline, 2008
Table 11.1 Biogen Idec Revenues ($m), 2003-2007
Table 11.2 Biogen Idec: Total Corporate Revenues ($m), 2008-2023
Table 11.3 Biogen Idec's Leading Drugs ($m), 2006-2007
Table 11.4 Biogen Idec's Geographical Sales ($m), 2006-2007
Table 11.5 Biogen Idec's Top-Two Drugs - Total Sales ($m) Forecast, 2008-2013
Table 11.6 Biogen Idec's Phase III Pipeline, 2008
Table 12.1 CSL Revenues and Net Profit ($m), 2003-2007
Table 12.2 CSL: Total Corporate Revenues ($m), 2008-2023
Table 12.3 CSL's Leading Drugs ($m), 2006-2007
Table 12.4 CSL's Geographical Sales ($m), 2007
Table 12.5 CSL's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Table 12.6 CSL's Phase III Pipeline, 2008
Table 13.1 Cephalon's Revenues ($m), 2003-2007
Table 13.2 Cephalon: Total Corporate Revenues ($m), 2008-2023
Table 13.3 Cephalon's Leading Drugs ($m), 2006-2007
Table 13.4 Cephalon's Geographical Sales ($m), 2007
Table 13.5 Cephalon's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Table 13.6 Cephalon's Phase III Pipeline, 2008
Table 14.1 Celgene's Revenues ($m), 2003-2007
Table 14.2 Celgene: Total Corporate Revenues ($m), 2008-2023
Table 14.3 Celgene's Leading Drugs ($m), 2006-2007
Table 14.4 Celgene's Geographical Sales ($m), 2006-2007
Table 14.5 Celgene's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Table 14.6 Celgene's Phase III Pipeline, 2008
Table 15.1 Actelion Revenues and Net Profit ($m), 2003-2007
Table 15.2 Actelion: Total Corporate Revenues ($m), 2008-2023
Table 15.3 Actelion's Leading Drugs ($m), 2006-2007
Table 15.4 Actelion's Geographical Sales ($m), 2006-2007
Table 15.5 Actelion's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Table 15.6 Actelion's Phase III Pipeline, 2008
List of Figures
Figure 3.1 Global Biotech Market Revenues ($m) Forecast 2008-2023
Figure 3.2 Global Biotech Market Share (%), 2007
Figure 3.3 Big Pharma Biotech Market Share (%), 2007
Figure 3.4 Top-10 Biotech Companies Market Share (%), 2007
Figure 4.1 Biotech Market Capitalisation ($bn) over 10-Year Period 1997-2007
Figure 5.1 Top-10 Biotech Market Revenues ($m) Forecast, 2008-2023
Figure 6.1 Amgen Revenues ($m), 2003-2007
Figure 6.2 Amgen Net Income ($m), 2003-2007
Figure 6.3 Amgen: Total Corporate Revenues ($m), 2008-2023
Figure 6.4 Amgen's Leading Drugs: Contribution to Company Sales (%), 2007
Figure 6.5 Amgen's Geographical Sales (%), 2007
Figure 6.6 Amgen's Top-Three Drugs – Total Sales ($m) Forecast, 2008-2013
Figure 7.1 Genentech Revenues ($m), 2003-2007
Figure 7.2 Genentech Net Income ($m), 2003-2007
Figure 7.3 Genentech: Total Corporate Revenues ($m), 2008-2023
Figure 7.4 Genentech's Leading Drugs: Contribution to Company Sales (%), 2007
Figure 7.5 Genentech's Geographical Sales (%), 2007
Figure 7.6 Genentech's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Figure 8.1 UCB Revenues ($m), 2003-2007
Figure 8.2 UCB Net Profit ($m), 2003-2007
Figure 8.3 UCB: Total Corporate Revenues ($m), 2008-2023
Figure 8.4 UCB's Leading Drugs: Contribution to Company Sales (%), 2007
Figure 8.5 UCB's Geographical Sales (%), 2007
Figure 8.6 UCB's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Figure 9.1 Gilead Sciences Revenues ($m), 2003-2007
Figure 9.2 Gilead Sciences: Total Corporate Revenues ($m), 2008-2023
Figure 9.3 Gilead Sciences' Leading Drugs: Contribution to Company Sales (%), 2007
Figure 9.4 Gilead Sciences' Geographical Sales (%), 2007
Figure 9.5 Gilead Sciences' Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Figure 10.1 Genzyme Revenues ($m), 2003-2007
Figure 10.2 Genzyme: Total Corporate Revenues ($m), 2008-2023
Figure 10.3 Genzyme's Leading Drugs: Contribution to Company Sales (%), 2007
Figure 10.4 Genzyme Geographical Sales (%), 2006
Figure 10.5 Genzyme's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Figure 11.1 Biogen Idec Revenues ($m), 2003-2007
Figure 11.2 Biogen Idec: Total Corporate Revenues ($m), 2008-2023
Figure 11.3 Biogen Idec's Leading Drugs: Contribution to Company Sales (%), 2007
Figure 11.4 Biogen Idec's Geographical Sales (%), 2007
Figure 11.5 Biogen Idec's Top-Two Drugs - Total Sales ($m) Forecast, 2008-2013
Figure 12.1 CSL Revenues ($m), 2003-2007
Figure 12.2 CSL Net Profit ($m), 2003-2007
Figure 12.3 CSL: Total Corporate Revenues ($m), 2008-2023
Figure 12.4 CSL's Leading Drugs: Contribution to Company Sales (%), 2007
Figure 12.5 CSL's Geographical Sales (%), 2007
Figure 12.6 CSL's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Figure 13.1 Cephalon's Revenues ($m), 2003-2007
Figure 13.2 Cephalon: Total Corporate Revenues ($m), 2008-2023
Figure 13.3 Cephalon's Leading Drugs: Contribution to Company Sales (%), 2007
Figure 13.4 Cephalon's Geographical Sales (%), 2007
Figure 13.5 Cephalon's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Figure 14.1 Celgene's Revenues ($m), 2003-2007
Figure 14.2 Celgene: Total Corporate Revenues ($m), 2008-2023
Figure 14.3 Celgene's Leading Drugs: Contribution to Company Sales (%), 2007
Figure 14.4 Celgene's Geographical Sales (%), 2007
Figure 14.5 Celgene's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Figure 15.1 Actelion Revenues ($m), 2003-2007
Figure 15.2 Actelion Net Profit ($m), 2003-2007
Figure 15.3 Actelion: Total Corporate Revenues ($m), 2008-2023
Figure 15.4 Actelion's Leading Drugs: Contribution to Company Sales (%), 2007
Figure 15.5 Actelion's Geographical Sales (%), 2007
Figure 15.6 Actelion's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Companies Listed
Abbott
Abgenix
Actelion
Amgen
Anthrogenesis
AstraZeneca
Biogen Idec
Bristol-Myers Squibb
Cardiokine Biopharm
Celera Genomics
Celgene
Cephalon
Chugai
CoTherix
CSL Ltd
CuraGen
Eisai
Eli Lilly
EMEA
FDA
Genentech
Genzyme
Gilead Sciences
GlaxoSmithKline (GSK)
Human Genome Sciences
Immunex-
Incyte Genomics
Iomai Corporation
Johnson & Johnson (J&J)
MedImmune
Merck KGaA
MGI
Millennium Pharmaceuticals
Mundipharma
Myriad Genetics
Novartis
Novo Nordisk
Pfizer
Pharmion
Roche
Roche Centre for Medical Genomics (RCMG)
Sanofi-Aventis
Schering-Plough
Schwarz Pharma
Serono (now Merck Serono)
Signal Pharmaceuticals
Teva
UCB
US Congressional Budget Office (CBO)
Ventana Medical Systems
World Health Organisation (WHO)
Wyeth
Zenyaku
How to Order:
Please send me the following details:
-Company Name –
-Name of user -
-Email Address of user -
-Users' Job Title-
-Postal Address -
-Contact Telephone Number -
-Fax Number -
-EEC VAT Number (if applicable) -
We have two available payment options. You can choose to pay by invoice, which will have bank transfer details, or alternatively by credit card which would be the fastest method. If by credit card, the details required are:
-Type of card -
-Card number -
-Expiry date -
-Issue number (if applicable) -
-Security number (3 digits, or 4 digits for Amex cards) -
All details may be provided by replying to this email, on phone or sent through fax. On receipt of full payment, the report requested would be sent to the email address provided.
I look forward to hearing from you soon,
Kind Regards,
Arpan Desai
Marketing Executive
Direct Line: +44 (0)20 7549 9962
Unsubscribe: As a valued contact or customer of Visiongain, you are receiving this email with information that we believe will be relevant to you. If, however, you do not wish to receive future messages, please reply to this message, typing 'unsubscribe' in the subject box of your email.
We support responsible and ethical email marketing practices. Please know that we respect your right to be purged from this marketing campaign.
Please allow 48 hours to remove your email address. Thank you for your cooperation.
Terms and Conditions for management reports
By replying to this e-mail submitting your order for this product you have agreed without limitation or qualification to be bound by and to comply with these Terms and Conditions. You agree that you will not fail to complete any transaction after submitting an order to purchase a product or submit any order to purchase a product where you do not intend to complete the transaction.
Management Reports will only be sent on receipt of payment.
